Close
4

Quotient Sciences Quotient Sciences

X

Find Baricitinib manufacturers, exporters & distributors on PharmaCompass

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

US DMFs Filed

US DMFs Filed

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

0

Other Certificates

Other Certificates

0

Other Suppliers

Other Suppliers

API REF. PRICE (USD / KG)
INTERMEDIATES
DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

Europe

Europe

0

Canada

Canada

Australia

Australia

South Africa

South Africa

Uploaded Dossiers

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Looking for 1187594-09-7 / Baricitinib API manufacturers, exporters & distributors?

Baricitinib manufacturers, exporters & distributors 1

82

PharmaCompass offers a list of Baricitinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Baricitinib manufacturer or Baricitinib supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Baricitinib manufacturer or Baricitinib supplier.

PharmaCompass also assists you with knowing the Baricitinib API Price utilized in the formulation of products. Baricitinib API Price is not always fixed or binding as the Baricitinib Price is obtained through a variety of data sources. The Baricitinib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Baricitinib

Synonyms

1187594-09-7, Olumiant, Incb028050, Ly3009104, 2-(3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile, Incb 028050

Cas Number

1187594-09-7

Unique Ingredient Identifier (UNII)

ISP4442I3Y

About Baricitinib

Baricitinib is an orally bioavailable inhibitor of Janus kinases 1 and 2 (JAK1/2), with potential anti-inflammatory, immunomodulating and antineoplastic activities. Upon administration, baricitinib binds to JAK1/2, which inhibits JAK1/2 activation and leads to the inhibition of the JAK-signal transducers and activators of transcription (STAT) signaling pathway. This decreases the production of inflammatory cytokines and may prevent an inflammatory response. In addition, baricitinib may induce apoptosis and reduce proliferation of JAK1/2-expressing tumor cells. JAK kinases are intracellular enzymes involved in cytokine signaling, inflammation, immune function and hematopoiesis; they are also upregulated and/or mutated in various tumor cell types.

Baricitinib Manufacturers

A Baricitinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Baricitinib, including repackagers and relabelers. The FDA regulates Baricitinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Baricitinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Baricitinib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Baricitinib Suppliers

A Baricitinib supplier is an individual or a company that provides Baricitinib active pharmaceutical ingredient (API) or Baricitinib finished formulations upon request. The Baricitinib suppliers may include Baricitinib API manufacturers, exporters, distributors and traders.

click here to find a list of Baricitinib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Baricitinib USDMF

A Baricitinib DMF (Drug Master File) is a document detailing the whole manufacturing process of Baricitinib active pharmaceutical ingredient (API) in detail. Different forms of Baricitinib DMFs exist exist since differing nations have different regulations, such as Baricitinib USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Baricitinib DMF submitted to regulatory agencies in the US is known as a USDMF. Baricitinib USDMF includes data on Baricitinib's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Baricitinib USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Baricitinib suppliers with USDMF on PharmaCompass.

Baricitinib KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a Baricitinib Drug Master File in Korea (Baricitinib KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Baricitinib. The MFDS reviews the Baricitinib KDMF as part of the drug registration process and uses the information provided in the Baricitinib KDMF to evaluate the safety and efficacy of the drug.

After submitting a Baricitinib KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Baricitinib API can apply through the Korea Drug Master File (KDMF).

click here to find a list of Baricitinib suppliers with KDMF on PharmaCompass.

Baricitinib NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Baricitinib as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Baricitinib API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Baricitinib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Baricitinib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Baricitinib NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Baricitinib suppliers with NDC on PharmaCompass.

Baricitinib GMP

Baricitinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Baricitinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Baricitinib GMP manufacturer or Baricitinib GMP API supplier for your needs.

Baricitinib CoA

A Baricitinib CoA (Certificate of Analysis) is a formal document that attests to Baricitinib's compliance with Baricitinib specifications and serves as a tool for batch-level quality control.

Baricitinib CoA mostly includes findings from lab analyses of a specific batch. For each Baricitinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Baricitinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Baricitinib EP), Baricitinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Baricitinib USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY